Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Chief Development & Regulatory Brenner Randall B. sold 7,674 shares of the company stock in a transaction that occurred on October 3, 2019.
The shares were sold at an average price of $ 3.98, for a total transaction of $ 30.54 thousand.
Following the completion of the transaction, the Chief Development & Regulatory now owns 91.34 thousand shares in the company, valued at approximately 363.53 thousand.
The transaction was disclosed in a filing with the SEC, which is available through SEC Filing Link.
According to the previous trading day, closing price of PRTK was $ 3.92, representing a 26.79 % increase from the 52 week low of $ 2.87 and a 195.15 % decrease over the 52 week high of $ 11.57.